Circular No. 37/2025/TT-BYT amends Circular No. 05/2024/TT-BYT regarding the list of medicines, medical devices, and laboratory supplies subject to price negotiation in tendering. This document specifies the adjustments related to the name of the managing unit and detailed information about certain types of medicines.
적용 범위
Medical facilities, pharmaceutical production and trading enterprises, medical device manufacturers, the Ministry of Health, and relevant agencies.
핵심 사항
- Replace the phrase 'Prevention of HIV/AIDS Department' and 'Preventive Medicine Department' with 'Disease Control Department' in Article 7 and Article 23 (Article 1).
- Amend the information on medicines with serial numbers 3 and 4 in Appendix I on the list of medicines, including active ingredients/concentrations, dosage forms, and units of measurement (Article 2).
- This Circular takes effect from August 7, 2025.
- Medical facilities must comply with the list of medicines, medical devices, and laboratory supplies specified in this Circular when applying the price negotiation method (Article 1).
- Detailed information about specific types of medicines such as the DPT-Hib-HBV vaccine must follow the updated information in Appendix I of this Circular.
🌐 이 문서의 사회적 영향
- Positive impact: Ensuring the accuracy and updating of the list of medicines, medical devices, and laboratory supplies; assisting medical facilities in complying with regulations when selecting contractors.
- Negative impact: Related entities need time to adjust information according to this new Circular.
❓ 자주 묻는 질문
Circular No. 37/2025/TT-BYT replaces which phrases?
Replace the phrases 'Prevention of HIV/AIDS Department' and 'Preventive Medicine Department' with 'Disease Control Department'.
When does this Circular take effect?
This Circular takes effect from August 7, 2025.
Circular No. 37/2025/TT-BYT amends detailed information about medicines with which serial numbers?
Amend the information on medicines with serial numbers 3 and 4 in Appendix I.
What does this Circular specify in detail?
Specifies the list of medicines, medical devices, and laboratory supplies subject to price negotiation in tendering.
How must medical facilities comply with this Circular?
Must comply with the list of medicines, medical devices, and laboratory supplies specified in this Circular when applying the price negotiation method.
전문
|
MINISTRY OF HEALTH |
SOCIALIST REPUBLIC OF VIET NAM |
|
NUMBER: 37/2025/TT-BYT |
HA NOI, AUGUST 7, 2025 |
CIRCULAR
AMENDMENT AND SUPPLEMENT TO CIRCULAR NO. 05/2024/TT-BYT OF MAY 14, 2024, ISSUED BY THE MINISTER OF HEALTH ON THE LIST OF MEDICINES, MEDICAL DEVICES, AND LABORATORY SUPPLIES APPLYING NEGOTIATED PRICING AND PROCEDURES FOR SELECTION OF CONTRACTORS FOR PROCUREMENT PACKAGES APPLYING NEGOTIATED PRICING
Pursuant to the Law on Bidding 2023, amended and supplemented in 2024 and 2025;
Pursuant to Decree No. 214/2025/NĐ-CP dated August 4, 2025, issued by the Government detailing certain provisions and measures for implementation of the Law on Bidding regarding selection of contractors;
Pursuant to Decree No. 42/2025/NĐ-CP dated February 27, 2025 of the Government stipulating the functions, tasks, powers, and organizational structure of the Ministry of Health;
At the proposal of the Director of the Department of Planning and Finance and the Director of the Drug Administration,
The Minister of Health issues this Circular amending and supplementing Circular No. 05/2024/TT-BYT dated May 14, 2024, issued by the Minister of Health on the list of medicines, medical devices, and laboratory supplies applying negotiated pricing and procedures for selection of contractors for procurement packages applying negotiated pricing.
Article 1. Amending and supplementing Circular No. 05/2024/TT-BYT dated May 14, 2024, issued by the Minister of Health on the list of medicines, medical devices, and laboratory supplies applying negotiated pricing and procedures for selection of contractors for procurement packages applying negotiated pricing
1. Replacing the phrase "Prevention of HIV/AIDS Department" and the phrase "Preventive Medicine Department" at Point a and Point c Clause 1 Article 7, Article 23 with the phrase "Disease Control Department".
2. Amending and supplementing information on medicine with serial number 3 and 4 in Section C Part II Appendix I promulgated together with Circular No. 05/2024/TT-BYT dated May 14, 2024 as follows:
|
Serial number |
Component/Active substance |
Concentration, content |
Formulation |
Unit of Measurement |
|
3 |
Diphtheria Toxoid; Tetanus Toxoid; Whole Cell Pertussis Antigen; Hepatitis B Surface Antigen (HBsAg) (rDNA); Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated with Tetanus Toxoid (carrier protein) |
Each dose of 0.5 ml contains: Diphtheria Toxoid ≤ 25Lf (≥ 30 IU); Tetanus Toxoid ≥ 2.5Lf (≥ 40 IU); Whole Cell Pertussis Antigen ≤ 16OU (≥ 4 IU); Hepatitis B Surface Antigen (HBsAg) (rDNA) ≥ 10 mcg; Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated with Tetanus Toxoid (carrier protein) 10 mcg |
Injectable solution |
Bottle |
|
4 |
Purified Diphtheria Toxoid; Purified Tetanus Toxoid; Whole Cell Pertussis Antigen; Purified Hepatitis B Surface Antigen (r-HBsAg); Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated with Tetanus Toxoid |
One dose of vaccine 0.5 ml contains: Purified Diphtheria Toxoid 25Lf (≥ 30 IU); Purified Tetanus Toxoid 5.5Lf (≥ 60 IU); Whole Cell Pertussis Antigen 16IOU (≥ 4 IU); Purified Hepatitis B Surface Antigen (r-HBsAg) 12.5 mcg; Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated with Tetanus Toxoid (20-36.7 mcg) 11 mcg. |
Injectable solution |
Bottle |
Article 2. Effective Date
This Circular takes effect from August 7, 2025.
During the implementation, if there are any difficulties, please report them to the Ministry of Health for consideration and resolution./.
|
|
DEPUTY MINISTER |
원본 문서(PDF)
관계도
문서를 클릭하면 열립니다. 빨간 테두리＝효력을 변경하는 관계.
번역본
이 문서는 다음 언어로 제공됩니다: